Abstract Purpose Pharmacist management of care for patients with inflammatory bowel disease (IBD) encompasses therapy education and optimization, monitoring, adherence support, and immunosuppression safety processes and thereby holds substantial promise for improving patient outcomes. However, the absence of a structured set of quality measures often results in fragmented efforts among clinic-based pharmacists, specialty pharmacy pharmacists, and managed care pharmacists. To address this shortcoming, we used an established modified Delphi process to develop and prioritize pharmacist-driven quality measures for the care of patients with IBD. Methods This multisite project was conducted at Mayo Clinic in Minnesota, Arizona, and Florida from October 30, 2023, through February 6, 2024. Stakeholders included IBD physicians, clinic-based pharmacists in medication management services, specialty pharmacy pharmacists, managed care pharmacists, and pharmacy leadership. An environmental scan identified existing quality measures, and a subsequent 3-round modified Delphi process was used to rate the quality measures for importance, feasibility, and validity before final ranking and consensus review. Results Thirty-one potential quality measures were identified. We prioritized 10 quality measures that emphasized adherence, safety screening, and timeliness of treatment initiation. These consensus-derived quality measures provided a foundation for systemwide performance tracking and quality improvement in pharmacist-led IBD care. Conclusion Prioritized quality measures were successfully identified to create a consistent, systemwide quality framework for pharmacist-led IBD care. Implementation of shared documentation standards and electronic health record–embedded tools are critical next steps to streamline efforts and monitor their effects on the quality of care for patients with IBD.